Metoclopramide for Acute Upper GI Bleeding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-10

Study Completion Date

2022-10-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The presence of blood clot in stomach limited quality of endoscopic view ,which affect successful rate of hemostatic endoscopy in patient with acute upper gastrointestinal bleeding. The study is aimed to evaluate the efficacy of metoclopramide, as pro-kinetic agent ,for gastric visualization in the patient with acute UGIB; double-blind randomized controlled trial and two centers study. The patient were randomly assigned to receive either metoclopramide (10mg) intravenously or placebo before endoscopy 30-120 min. The primary endpoint was endoscopic yield, assessed by objective gastric visualized scoring systems. Secondary end points include duration of endoscope, technical success rate, the need for second-look EGD, units of blood transfusion, length of hospital stay and 30-day rebleeding rate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metoclopramide for Gastric Visualization in Active Upper GI Bleeding

NCT06167837

Upper GI Bleeding

RECRUITING PHASE4

Metoclopramide in Upper Gastrointestinal Bleed

NCT05746377

Upper GI Bleeding Bleeds Gastric Bleed Ulcer +2 more

UNKNOWN PHASE4

Usefulness of Metoclopramide to Improve Endoscopic Visualization in Upper Gastrointestinal Bleeding

NCT06297954

Upper Gastrointestinal Bleeding

COMPLETED PHASE3

Efficacy of Itopride Versus Metoclopramide in Hospitalized Medicine Patients With High Gastric Residual Volume

NCT07031479

Feeding Intolerance

NOT_YET_RECRUITING PHASE4

Study to Evaluate the Efficacy of Oral Dissolving Metoclopramide Before Video Capsule Endoscopy

NCT01631994

Gastric Transit Time

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Double-blind, Double centers, RCT
* All endoscopists at two participating sites attend the pre-study meeting for standardization of protocol and scoring system.
* Eligible patients were randomly assigned to either metoclopramide or placebo group in a 1:1 conceal allocation according to a computer-generated randomization list with block randomization in size of four.
* Assigned treatment was kept in opaque sealed envelopes.
* Before EGD, the patients had adequate resuscitation to maintain stable hemodynamics(SBP ≥ 90 mmHg and/or HR \< 100 bpm) and blood transfusion to reach Hb\> 7g/dL and correct coagulopathy.
* EGD is performed in left lateral position, under local lidocaine anesthesia alone or combined with IV anesthetics
* The standardized set of endoscopic landmarks, including the esophagus, gastro-esophageal junction, fundus, gastric body, incisura, antrum, duodenal bulb, and second part of the duodenum were examined.
* To assess endoscopic gastric visualization, we applied simple validate objective scoring system and estimated coverage of blood clot on mucosa on reference endoscopies view in 4 locations, including fundus, corpus, antrum and duodenal bulb.
* Each location is scored between 0 and 2; Score 0 (worst vision) \< 25% of the surface was visible; Score 1 25-75% visible surface; Score 2 (best vision), \> 75% visible surface ( total score range 0-8)
* 'Adequate visualization' defined as total score six or higher (out of 8).
* All photos of endoscopic landmark, including the reference endoscopic views of four locations (fundus, corpus antrum and duodenal bulb), were taken and internally validated by another endoscopist who was blinded to the randomization allocation.
* The duration of the endoscopy was recorded from beginning to end of the procedure in minute.
* The 72-hour recurrent GI bleeding was documented and re-EGD was performed to confirm rebleeding if the following conditions were met

: I) hematemesis or bloody NG \> 6 hours after endoscopy; II) melena after normalization of stool color; III) hematochezia after normalization of stool color or melena; IV) development of tachycardia (HR ≥ 110 bpm) or hypotension(SBP ≤ 90 mmHg) after ≥ 1 hour of vital sign stability without other cause; V) hemoglobin drop of ≥ 2 g/dL after two consecutive stable hemoglobin values ( \< 0.5 g/dL decrease) ≥ 3 hours apart; VI) tachycardia or hypotension that does not resolve within 8 hours after index endoscopy despite appropriate resuscitation (in the absence of an alternative explanation), associated with persistent melena or hematochezia or; VII) persistently dropping hemoglobin of \> 3 g/dL in 24 hours associated with persistent melena or hematochezia.
* 30-day rebleeding is accessed by direct phone call to patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Upper Gastrointestinal Bleeding Effect of Drug

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

* Double-blind, Double centers, RCT
* The standardized set of endoscopic landmarks, including the esophagus, gastro-esophageal junction, fundus, gastric body, incisura, antrum, duodenal bulb, and second part of the duodenum were examined.
* The simple validate objective scoring system was applied; estimated coverage of blood clot on mucosa on reference endoscopies view in 4 locations, including fundus, corpus, antrum and duodenal bulb.
* Each location was scored between 0 and 2 Score 0 (worst vision), less than 25% of the surface was visible Score 1 25-75% visible surface Score 2 (best vision), more than 75% visible surface ( total score range 0-8)
* 'Adequate visualization' = total score six or higher.
* All photos was internally validated by another endoscopist who was blinded to the randomization allocation.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

All participating endoscopists and patients were blinded to the randomization allocation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

metoclopramide

Metoclopramide 10mg with normal saline up to 10 ml IV slowly push in 5minutes.

Group Type EXPERIMENTAL

Metoclopramide

Intervention Type DRUG

Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min

placebo

Normal saline 10 ml IV slowly push in 5 minutes.

Group Type PLACEBO_COMPARATOR

Normal Saline 10 mL Injection

Intervention Type DRUG

Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metoclopramide

Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min

Intervention Type DRUG

Normal Saline 10 mL Injection

Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \>= 18 years
2. Active upper GI bleeding ( defined as fresh or bright red hematemesis within 24hr. or presented of blood via NG aspiration )
3. Underwent upper GI endoscopy within 12hr
4. Informed consent obtained

Exclusion Criteria

1. Known allergy of metoclopramide
2. History of gastric or duodenal surgery
3. Known case esophageal, gastric or duodenal cancer
4. Diagnosed with advanced HIV infection (defined as CD4 cell count \<200 cells/mm3 or WHO clinical stage 3 or 4)
5. Pregnancy or lactating
6. NG lavage was done with solution \> 50 ml.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rapat Pittayanon

MD, MSc (Medicine and Experimental Surgery) Associate Professor, Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University Secretary General, the Gastroenterological Association of Thailand (GAT)

Responsibility Role PRINCIPAL_INVESTIGATOR